Menu
Fechar
HRS4R
Vull donar
Firma
JOAQUIM BOSCH-BARRERA
Posició
Cap de Grup - R4
Caps de Grup - R4
Projectes
Publicacions
Propietat intel·lectual

Projectes

Oncologia de Precisió de Girona

Estudio descriptivo y efecto del ritmo circadiano en el tratamiento con quimio-inmunoterapia neoadyuvante del cáncer del pulmón de célula no pequeña en estadios precoces. Un estudio multicéntrico con resultados de Real World Data (RWD)

Codi oficial: 2024_GECP_CMF Data inici: 01/12/2024 Data fi: 30/11/2026 Investigador/a principal: CLAUDIA MONTAÑES FERRER Organisme finançador: GRUPO ESPAÑOL DE CANCER DE PULMON
Oncologia de Precisió de Girona

Identificación de biomarcadores relacionados con la inmunoterapia en cáncer de pulmón: Integración de datos poblacionales y biopsia líquida con enfoque en pacientes con metástasis cerebrales

Codi oficial: CLJUN258531TEIX Data inici: 01/11/2025 Data fi: 30/10/2028 Investigador/a principal: JOAQUIM BOSCH BARRERA, EDUARD TEIXIDOR VILA Organisme finançador: ASSOCIACIÓ ESPANYOLA CONTRA EL CÀNCER

Publicacions

Bosch-Barrera J, Estévez-García P, Martín-Martorell P, Sabatier R, Nadal E, Sais E, Gascón P, Oaknin A, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfón J, Domènech C, Morán T

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.

LUNG CANCER, 2025, 201, 108105-108105 dx.doi.org/10.1016/j.lungcan.2025.108105
Sabaté-Ortega, J, Teixidor-Vilà, E, Sais, E, Hernandez-Martínez, A, Montañés-Ferrer, C, Coma, N, Polonio-Alcalá, E, Pineda, V, Bosch-Barrera, J

Cardiovascular toxicity induced by immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis of observational studies

Frontiers in oncology, 2025, 15 dx.doi.org/10.3389/fonc.2025.1528950
López, J, Llop-Hernández, A, Verdura, S, Serrano-Hervás, E, Martinez-Balibrea, E, Bosch-Barrera, J, Teixidor, E, López-Bonet, E, Martin-Castillo, B, Sardanyés, J, Alarcón, T, Lupu, R, Cuyàs, E, Menendez, JA

Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies

Cell Death Discovery, 2025, 11, 91-91 dx.doi.org/10.1038/s41420-025-02379-y
Chouaid C, Grossi F, Ta Thanh Minh C, Raymond R, Bosch-Barrera J

Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLC.

Lung Cancer Management, 2025, 14, 2477418-2477418 dx.doi.org/10.1080/17581966.2025.2477418
Bilionis I, Fernandez Luque L, Ponce Aix S, Bosch-Barrera J, Arnaiz P, Flores A

Data-Driven Assessment of Lung Cancer Patients Using Performance Status and Wearable Device Metrics.

Studies in Health Technology and Informatics, 2025, 323, 184-188 dx.doi.org/10.3233/SHTI250074
Bosch-Barrera J, Pérez-Montoyo H, Domènech C, Lizcano JM

Understanding Ibrilatazar's mechanism of action: Addressing concerns about autophagy in cancer Therapy.

LUNG CANCER, 2025, 203, 108538-108538 dx.doi.org/10.1016/j.lungcan.2025.108538
Xu Y, Yang JC, Zhao Y, Doucet L, Zhou J, Wang Y, Planchard D, Fan Y, Jin B, Han Z, Greillier L, Mazieres J, Sun M, Hu Y, Song X, Ding C, Wu L, Tang K, Liang L, Yao Y, Cheng Y, He Y, Ferreira BP, Ghiringhelli F, Felip E, Bosch-Barrera J, Liu A, Yu Y, Dong X, Gao J, Camidge DR, Nian W, Zhou C, Yang R, John T, Gao B, Bazhenova L, Nagasaka M, Wang J, Ren X, Xu F, Li W, Zhao D, Wang H, Sun S, Huang J, Zhu X, Zheng L, Jänne PA, Wang M

Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation.

CELL REPORTS MEDICINE, 2025, 6, 102121-102121 dx.doi.org/10.1016/j.xcrm.2025.102121
Bosch-Barrera, J, Sais, E, Teixidor-Vilà, E, Vásquez-Dongo, C, Hernandez-Martínez, A, Romera, A, Pinsach-Abuin, ML, del Olmo, B, Oliveras, G, Polonio-Alcalá, E, Verdura, S, Soriano-Gamero, M, Pineda, V, Rosales, H, Menendez, JA

The STAT3/TIMP1 inhibitor silibinin overcomes secondary immunoresistance to pembrolizumab in brain metastases from METex14 skipping mutated non-small cell lung cancer: a case report

Frontiers in Medicine, 2025, 12, 1612327-1612327 dx.doi.org/10.3389/fmed.2025.1612327
Provencio, M, Cobo, M, Rodriguez-Abreu, D, Carcereny, E, Castro, RL, Bruno, MF, Bernabé, R, Bosch-Barrera, J, Massuti, B, Sánchez, A, Ortega, AL, Guirado, M, del Barco, E, Camps, C, Lázaro-Quintela, M, Dómine, M, Sala, MA, Medina, K, González-Larriba, JL, Aparisi, F, Oramas, J, Aguiar, D, Cerezo, S, Losada, B, Ruano-Ravina, A, Cantero, A, Ospina-Serrano, AV, Calvo, V

Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain

LANCET REGIONAL HEALTH-EUROPE, 2025, 56 dx.doi.org/10.1016/j.lanepe.2025.101402
Provencio M, Cobo M, Rodriguez-Abreu D, Carcereny E, Calvo V, Castro RL, Bernabé R, Bruno MF, Bosch-Barrera J, Barco ED, Medina K, Sanchez-Hernandez A, Suay G, Ortega AL, Vázquez S, Lazaro-Quintela M, Guirado M, Estival A, Blanco M, Cantero A, Massutí B

Biomarker landscape in advanced NSCLC: insights from a national prospective registry.

LUNG CANCER, 2025, 207, 108680-108680 dx.doi.org/10.1016/j.lungcan.2025.108680

Propietat intel·lectual

Joaquim Bosch Barrera

MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS

Número de publicació: EP20170382891 Data de publicació: 2019-06-26

Formulari de contacte

Coneix l’IDIBGI!

 menu